Overview
- On Friday, June 5, 2026, three plaintiff firms — The Schall Law Firm, DJS Law Group and The Rosen Law Firm — issued notices inviting Immutep shareholders to join a filed securities class action.
- The complaint charges violations of Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5 based on public statements about Immutep’s clinical program.
- Plaintiffs point to a January 30, 2026 Form-K in which Immutep said its TACTI-004 trial showed “strong operational progress” while alleging the company knew the study risked failing its primary efficacy endpoints.
- The alleged class period runs from March 24, 2025 through March 12, 2026 and the firms set July 6, 2026 as the deadline to move for appointment as lead plaintiff.
- No class has been certified and the notices stress the allegations are unproven; if the case advances it will rely on discovery of internal trial data and expert proof before any recovery is possible.